Loading viewer...
investor_presentation
Format: PDF investor_presentation
Financial Results for the Quarter Ended March 31, 2018 May 2018 Nasdaq: MESO ASX:MSB
Financial Results for the
Quarter Ended March 31, 2018
Nasdaq: MESO ASX:MSB CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements . We make such forward-
looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this
presentation are forward-looking statements . Words such as, but not limited to, “believe, ” “expect, ” “anticipate, ” “estimate, ” “intend, ” “plan, ” “targets, ” “likely, ” “will,” “would, ” “could, ” and similar expressions or phrases identify
forward -looking statements . We have based these forward-looking statements largely on our current expectations and future events, recent changes in regulatory laws, and financial trends that we believe may affect our
financial condition, results of operation, business strategy and financial needs . These statements may relate to, but are not limited to: expectations regarding the safety or efficacy of, or potential applications for, Mesoblast's
adult stem cell technologies ; expectations regarding the strength of Mesoblast's intellectual property, the timeline for Mesoblast's regulatory approval process, and the scalability and efficiency of manufacturing processes ;
expectations about Mesoblast's ability to grow its business and statements regarding its relationships with current and potential future business partners and future benefits of those relationships ; statements concerning
Mesoblast's share price or potential market capitalization; and statements concerning Mesoblast's capital requirements and ability to raise future capital, among others . Forward -looking statements should not be read as a
guarantee of future performance or results, and actual results may differ from the results anticipated in these forward -looking statements, and the differences may be material and adverse. You should read this presentation
together with our financial statements and the notes related thereto, as well as the risk factors, in our most recently filed reports with the SEC or on our website . Uncertainties and risks that may cause Mesoblast's actual
results, performance or achievements to be materially different from those which may be expressed or implied by such statements, include, without limitation : risks inherent in the development and commercialization of
Preview truncated — download the full document for the complete content.
presentation
Adriatic Metals August 2021 Investor Presentation - Balkans Mining
investor_presentation
28 Pages
Adriatic Metals
investor_presentation
Adient
Basilea Pharmaceutica 2020 Investor Presentation
investor_presentationinvestor_presentation
27 Pages
Basilea Pharmaceutica International Ltd.
investor_presentation
APA Group